Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib

This study has been completed.
Information provided by (Responsible Party):
Genentech, Inc. Identifier:
First received: January 17, 2013
Last updated: November 1, 2016
Last verified: November 2016
This randomized, open-label, 4-arm, multiple-dose study will evaluate the effect of coadministration of a protein pump inhibitor, an inhibitor of P-glycoprotein and CYP3A4, or an inhibitor of CYP2C9 on the pharmacokinetics of vismodegib in healthy female subjects of non-childbearing potential. Subjects will be randomized to receive multiple oral doses of vismodegib, alone or in combination with multiple oral doses of either rabeprazole, itraconazole or fluconazole. Anticipated time on study treatment is up to 11 days.

Condition Intervention Phase
Healthy Volunteer
Drug: fluconazole
Drug: itraconazole
Drug: rabeprazole
Drug: vismodegib
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: A Clinical Drug-Drug Interaction Study to Evaluate the Effect of a Proton Pump Inhibitor, a Combined P-gp/CYP3A4 Inhibitor, and a CYP2C9 Inhibitor on the Pharmacokinetics of Vismodegib

Resource links provided by NLM:

Further study details as provided by Genentech, Inc.:

Primary Outcome Measures:
  • Relative effect of rabeprazole on steady-state pharmacokinetics of vismodegib: Area under the concentration-time curve (AUC)/Steady-state concentration (Css) [ Time Frame: up to 12 days ]
  • Relative effect of itraconazole on steady-state pharmacokinetics of vismodegib: Area under the concentration-time curve (AUC)/Steady-state concentration (Css) [ Time Frame: up to 12 days ]
  • Relative effect of fluconazole on the steady-state pharmacokinetics of vismodegib: Area under the concentration-time curve (AUC)/Steady-state concentration (Css) [ Time Frame: up to 12 days ]

Enrollment: 92
Study Start Date: February 2013
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A: Vismodegib Drug: vismodegib
Multiple oral doses
Experimental: B: Rabeprazole + Vismodegib Drug: rabeprazole
Multiple oral doses
Drug: vismodegib
Multiple oral doses
Experimental: C: Itraconazole + Vismodegib Drug: itraconazole
Multiple oral doses
Drug: vismodegib
Multiple oral doses
Experimental: D: Fluconazole + Vismodegib Drug: fluconazole
Multiple oral doses
Drug: vismodegib
Multiple oral doses


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Females of non-childbearing potential
  • Body mass index (BMI) 18 to 32 kg/m2, inclusive
  • In good health, determined by no clinically significant findings from medical history, physical examination. 12-lead ECG, and vital signs
  • Clinical laboratory evaluations, complete blood count and urinalysis within the normal range for the test laboratory, unless not deemed clinically significant by the investigator
  • Negative test for drugs of abuse at screening and check-in (including alcohol)
  • Negative for hepatitis B, hepatitis C and HIV infection
  • Non-childbearing potential is defined as: non-pregnant, non-lactating, and either postmenopausal for at least 1 year or surgically sterile (e.g. bilateral oophorectomy and/or hysterectomy)

Exclusion Criteria:

  • Significant history or clinical evidence of any metabolic (including type 1 or 2 diabetes). allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, endocrine, GI (including gastric or duodenal ulcers), Zollinger-Ellison syndrome, Barrett's esophagus, urological, neurological, or psychiatric disorder
  • History of inflammatory arthritis
  • History of symptomatic hypotension
  • History of seizure disorders
  • History of bipolar or major depressive disorder
  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (appendectomy, hernia repair, and/or cholecystectomy will be allowed)
  • History of alcoholism or drug addiction within 1 year prior to check-in
  • Use of any tobacco- or nicotine-containing products within 6 months prior to check-in
  • Participation in any other investigational study drug or biological agent trial in which receipt of investigational study drug occurred within 5 half-lives or 30 days, whichever is longer, prior to check-in
  • Use of PPIs, H2-receptor antagonists, or antacids within 1 month prior to check-in
  • History of chronic PPI use (> 30 days of continuous daily dosing) within 6 months of check-in
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01772290

United States, Florida
Daytona Beach, Florida, United States, 32117
United States, Texas
Dallas, Texas, United States, 75247
Sponsors and Collaborators
Genentech, Inc.
Study Director: Clinical Trials Genentech, Inc.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Genentech, Inc. Identifier: NCT01772290     History of Changes
Other Study ID Numbers: GP28465
Study First Received: January 17, 2013
Last Updated: November 1, 2016

Additional relevant MeSH terms:
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inhibitors
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 CYP2C19 Inhibitors processed this record on May 25, 2017